hotspot -WSS

hotspot

author：focus 2025-09-02 08:15:40 - browse：127

3d rendered medically accurate illustration of the adrenal gland – biotech and pharma coverage from STAT — Adobe

SAN DIEGO — Neurocrine Biosciences announced on Tuesday that an experimental drug for congenital adrenal hyperplasia succeeded in a late-stage trial, bringing the company a step closer to treating patients with a rare and serious set of genetic disorders that alters their ability to produce key hormones.

In the Phase 3 study, known as CAHtalyst, 182 adults were randomly assigned to receive a placebo or crinecerfont, an oral drug Neurocrine developed to lower male sex hormones patients with the disease produce in excess. Researchers found that, compared to those on placebo, participants who took crinecerfont needed a significantly lower dose of the current standard-of-care treatment, glucocorticoids, after 24 weeks of treatment that they did at the study’s start. And about 63% of participants who took crinecerfont were able to lower their dose of glucocorticoids to levels researchers think would be safer for prolonged use, compared to 18% of those on the placebo.

Neurocine, a San Diego biotech focused on treating rare neurological and endocrine diseases, believes the drug could allow people living with congenital adrenal hyperplasia, or CAH, to avoid some of the more serious side effects of glucocorticoids by allowing them to take lower doses. Long-term use of high doses of these drugs can cause patients to gain weight and put them at risk of diabetes, heart disease, and osteoporosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： H5N1 bird flu virus started spreading in cows in Texas in December

WSS

Dogs on Prozac: What pet anti

FTC falls short on scrutinizing hospital mergers, study says

U.K. officials, researchers try to ease path for bespoke genetic treatments

More tobacco lobbyists active in statehouses

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

Dogs on Prozac: What pet anti

hotspot

hotspot

hotspot

Tori Bowie and the unacceptable rates of Black maternal death

'Patient friction coefficient' can gauge a clinical trial's patient burden

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

UnitedHealth financials solid despite Change Healthcare cyberattack

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Cue Health's Covid

At least 13 dead in Texas as scorching temps continue

Bring on the sabbaticals for nurses

United colonoscopy coverage change 'may cost lives,' doctors say

Pfizer, Moderna say biotech, pharma drug development is a sprint

focus

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

This gene therapy has record $4.25 million price. It's saved children.

Exact Sciences stock tumbles despite strong cancer detection sales

Mirador, a new biotech startup, launches with $400 million

MassMutual is introducing free genetic testing for members

Cue Health's Covid

Wikipedia

entertainment

leisure time

entertainment